Innovative Patient-partner-guided Virtual Group Speech Pathology Intervention Model in Head and Neck Cancer

Impacts of an Innovative Patient-partner-guided Virtual Group Speech Pathology Intervention Model to Prevent Swallowing Disorders in Patients Treated With Chemoradiotherapy for Head and Neck Cancer

Status

Recruiting

Phases

Phase 1Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05621889

Enrollment

Registered

2022-11-18

Start date

2023-06-02

Completion date

2026-01-31

Last updated

2025-03-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dysphagia

Brief summary

This project aims to study an innovative intervention, the eG2 Intervention, developed by speech-language pathologists at the Centre hospitalier de l'Université de Montréal to improve therapeutic adherence and prevent dysphagia in patients treated with chemoradiotherapy for head and neck cancer. The innovation consists in offering a speech therapy intervention that is 1) virtual, 2) group-based (whereas it is usually individual) and 3) involves a patient partner. This intervention has the potential to improve quality of care, accessibility to services and optimize health care resources.

Interventions

PROCEDUREvirtual group speech therapy intervention guided by a patient partner

virtual group speech therapy intervention guided by a patient partner

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Adults ≥ 18 years of age with a diagnosis of head or neck cancer * Chemoradiotherapy treatments planned for curative purposes * Planned external radiation therapy dose of at least ≥60 Grays * Sufficient proficiency in French to complete self-reported questionnaires

Exclusion criteria

* Remote metastases * Previous or planned total laryngectomy * Previous moderate/severe dysphagia known and/or evaluated by speech therapy * Diagnosis of a second synchronous cancer at the time of study enrollment * History of prior radiation therapy to the head and neck area * Have a cognitive impairment (diagnosed or suspected) that may significantly interfere with participation in the intervention and various measurement procedures.

Design outcomes

Primary

Measure	Time frame	Description
Rate of nasogastric tube	within 6 weeks post radiation	To evaluate the rate of nasogastric tube placement in the acute and subacute period in patients who participated in the group intervention.

Countries

Canada

Contacts

Primary ContactMarie-Eve Caty, M.P.O., Ph.D.

marie-eve.caty@uqtr.ca819 376-5011

Backup ContactHouda Bahig, MD PhD

houda.bahig.med@ssss.gouv.qc.ca514-890-8254

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026